Balyasny Asset Management LLC Immuneering Corp Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
Shares
1 transactions
Others Institutions Holding IMRX
# of Institutions
52Shares Held
11.6MCall Options Held
0Put Options Held
0-
Cormorant Asset Management, LP Boston, MA3.3MShares$4.22 Million0.55% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$2.41 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$1.76 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.2MShares$1.54 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD910KShares$1.17 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $33.8M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...